Clinical Trial Search Results for "DISPERSE2-TIMI 33"

Cannon, C. P., Husted, S., Harrington, R. A., Scirica, B. M., Emanuelsson, H., Peters, G., Storey, R. F. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial J Am Coll Cardiol. 2007;50(19):1844-51. Abstract

Storey, R. F., Husted, S., Harrington, R. A., Heptinstall, S., Wilcox, R. G., Peters, G., Wickens, M., Emanuelsson, H., Gurbel, P., Grande, P., Cannon, C. P. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol. 2007;50(19):1852-6. Abstract

Husted, S., Harrington, R. A., Cannon, C. P., Storey, R. F., Mitchell, P., Emanuelsson, H. Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial Int J Clin Pract. 2009;63(4):667-70. Abstract

Storey, R. F., Melissa Thornton, S., Lawrance, R., Husted, S., Wickens, M., Emanuelsson, H., Cannon, C. P., Heptinstall, S., Armstrong, M. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3 Platelets. 2009;20(5):341-8. Abstract

Syed, Z., Scirica, B. M., Mohanavelu, S., Sung, P., Michelson, E. L., Cannon, C. P., Stone, P. H., Stultz, C. M., Guttag, J. V. Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphology Am J Cardiol. 2009;103(3):307-11. Abstract

Husted, S., Storey, R. F., Harrington, R. A., Emanuelsson, H., Cannon, C. P. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel Clin Cardiol. 2010;33(4):206-12. Abstract